AbbVie Inc. (NYSE: ABBV), a prominent research-based pharmaceutical company, has confirmed its intention to acquire Apogee Therapeutics. This strategic move, announced on June 22, will see AbbVie incorporate Apogee's diverse range of clinical-stage candidates, currently in development for immunological and inflammatory conditions such as asthma and atopic dermatitis. The leadership of AbbVie views this acquisition as a crucial step to complement its current immunology offerings and expand its involvement in the respiratory health sector.
The terms of the agreement stipulate that AbbVie will purchase all outstanding shares of Apogee at $135.11 per share in cash, reflecting a total equity valuation for Apogee of approximately $10.9 billion. This significant transaction has received unanimous approval from the boards of directors of both companies and is projected to finalize in the third fiscal quarter of 2026. The completion remains subject to standard closing conditions, including endorsement from Apogee shareholders and the receipt of necessary regulatory approvals.
AbbVie is recognized for its dedication to developing and commercializing treatments for various chronic diseases across multiple therapeutic areas, including oncology, gastroenterology, rheumatology, dermatology, and virology. This acquisition further underscores AbbVie's commitment to innovation and growth in critical health domains. Such strategic integrations demonstrate how established pharmaceutical entities seek to broaden their impact and address unmet medical needs, fostering advancements in patient care and global health initiatives.